A5091216622- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Multiple and Secondary Primary Cancers
- Inflammatory Biomarkers in Disease Prognosis
- Chronic Lymphocytic Leukemia Research
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Neutropenia and Cancer Infections
- Cancer Risks and Factors
- Cholesterol and Lipid Metabolism
- Lymphoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Neurological disorders and treatments
- Gastric Cancer Management and Outcomes
- PARP inhibition in cancer therapy
- Automotive and Human Injury Biomechanics
- Traumatic Brain Injury and Neurovascular Disturbances
- Neuroendocrine Tumor Research Advances
- Genetic Neurodegenerative Diseases
- Ferroptosis and cancer prognosis
- Traumatic Brain Injury Research
- Parkinson's Disease Mechanisms and Treatments
Marche Polytechnic University
2021-2025
Ospedali Riuniti di Ancona
2023
Azienda Ospedaliero Universitaria Ospedali Riuniti
2023
University of Padua
2019-2022
Background: The Gustave Roussy Immune (GRIm)-Score takes into account neutrophil-to-lymphocyte ratio (NLR), serum albumin concentration and lactate dehydrogenase (LDH) its prognostic value has been investigated in patients treated with immune check-point inhibitors (ICIs). To further assess the predictive of baseline GRIm-Score (GRImT0) advanced non-small cell lung cancer (aNSCLC) patients, we separately two cohorts first-line pembrolizumab or chemotherapy. We also whether at 45 days since...
Abstract Background Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown. Methods Characteristics 812 consecutive solid cancer who received at least 1 cycle ED monotherapy (pembrolizumab 400 mg Q6W or nivolumab 480 Q4W) after switching from canonical (CD; pembrolizumab 200 Q3W 240 Q2W) upfront were retrieved. The primary objective was to compare irAEs...
Immune checkpoint inhibitors (ICIs) have revamped the clinical outcomes of patients (pts) affected by advanced non-oncogene addicted non-small cell lung cancer (NSCLC). The aim our study is to develop an ensemble clustering algorithm (Clust) integrated with a logistic regression model (Pro) prognostically stratify NSCLC pts treated ICIs (NSCLC-Pro ClustAI). Data extraction involved, retrospectively, all consecutive at Department Medical Oncology, Ancona, Italy. Baseline features included...
e13605 Background: Immune checkpoint inhibitors (ICIs) have revamped the clinical outcomes of patients (pts) affected by advanced solid tumors. The aim our study is to develop a two-stage Gaussian Clustering algorithm (G2C) integrated with logistic regression model (Pro) prognostically stratifypts tumors treated ICIs (pan-cancer G2C-Pro) based on baseline features. Methods: Data extraction involved, retrospectively, pts (lung, melanoma, renal cancer, head and neck, urothelial carcinoma) at...
8584 Background: The nutritional status of patients (pts) with advanced cancer seems to impact on immune cells activity against tumor cells. We aim explore the prognostic role and body composition (BC) in pts non-small cell lung (NSCLC) treated checkpoint inhibitors (ICIs). Methods: From June 2021, we prospectively enrolled NSCLC ICIs, as monotherapy or combination chemotherapy. Pts at baseline was evaluated using controlling (CONUT) score (combining serum albumin, total cholesterol,...
To investigate the different impact of each component lipid profile in advanced cancer patients treated with immune checkpoints inhibitors (ICIs) according to neutrophil-to-lymphocyte ratio (NLR) value.
Tumor-Infiltrating Lymphocytes (TIL) are emerging as immunotherapy prognostic markers. Currently, TIL assessed on hematoxylin and eosin (H&E)-stained slides of tumor tissue by pathologists. This approach is time-consuming, subjected to inter-observer variability. The aim this study propose a machine learning-based algorithm, called Feature Engineering Assessment (FTA), for the automatic assessment using adenocarcinoma metadata (i.e., anamnestic, clinical pathological data). algorithm an...
2595 Background: Healthcare costs and need of frequent patients' (pts) access to oncology departments led an increasing interest in alternative immune check-point inhibitors (ICIs) administration schedules able offer longer dose intervals. The extended interval dosing (ED) nivolumab pembrolizumab was approved based on pharmacokinetic data, the relationship exposure efficacy, safety. We aimed investigate real-life immune-related adverse events (irAEs) incidence pts treated with ED-ICIs....